Nuvalent Submits NDA for neladalkib
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy NUVL?
Nuvalent announced the submission to the FDA of the company's NDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive NSCLC. "The advancement of neladalkib from first clinical trial initiation to NDA submission in less than four years represents a remarkable pace in oncology drug development, underscoring the vigor and urgency our team brought to this program and our deep commitment to the ALK-positive NSCLC community," said Darlene Noci, chief development officer at Nuvalent. "We would like to extend our sincere gratitude to the patients, families and investigators who have made this progress possible, and are committed to working closely with the FDA throughout the NDA review process toward our goal of bringing neladalkib to patients as quickly as possible."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 100.280
Low
125.00
Averages
140.86
High
158.00
Current: 100.280
Low
125.00
Averages
140.86
High
158.00
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Guardant Health and Nuvalent Forge Long-Term Partnership to Create Companion Diagnostics and Aid in the Commercialization of Targeted Cancer Treatments via the Guardant Infinity™ Platform
Strategic Collaboration Announcement: Guardant Health has announced a multi-year strategic collaboration with Nuvalent to develop companion diagnostics for targeted cancer therapies.
Focus on Cancer Therapies: The partnership aims to enhance the development of diagnostics that support the commercialization of specific cancer therapies.
Utilization of Technology: The collaboration will leverage the Guardant Infinity™ platform to facilitate advancements in cancer diagnostics.
Potential Impact: This initiative is expected to improve patient outcomes by providing tailored diagnostic solutions for targeted cancer treatments.
See More
Nuvalent Announces Clinical Trial Data Presentation
- Clinical Trial Data Presentation: Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC patients at the 2026 ASCO Annual Meeting, which is expected to attract investor interest and potentially drive stock price appreciation.
- NDA Progress: The FDA has accepted Nuvalent's NDA for zidesamtinib, with a target action date of September 18, 2026, which, if approved, will provide a new treatment option for patients with ROS1-positive NSCLC, enhancing the company's market competitiveness.
- Breakthrough Therapy Designation: Both neladalkib and zidesamtinib have received breakthrough therapy designation from the FDA, indicating their potential in treating resistant tumors, which may attract further investment and enhance the company's reputation.
- Global Clinical Trial Strategy: The global data presentation from the ARROS-1 and ALKOVE-1 trials demonstrates Nuvalent's ongoing innovation in targeted cancer therapies, potentially laying the groundwork for future market expansion.
See More
Nuvalent Presents Clinical Trial Data for Cancer Treatments
- Clinical Trial Data Presentation: Nuvalent will present pivotal data for neladalkib in ALK-positive non-small cell lung cancer patients at the 2026 ASCO Annual Meeting, which is expected to enhance its market position in oncology.
- NDA Progress: The FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, indicating significant market opportunities for the drug in ROS1-positive non-small cell lung cancer patients.
- Breakthrough Therapy Designation: Both neladalkib and zidesamtinib have received breakthrough therapy designation from the FDA, highlighting their potential in treating resistant tumors and likely attracting increased investor interest.
- Global Clinical Trial Strategy: The global scope of the ARROS-1 and ALKOVE-1 clinical trials demonstrates Nuvalent's strategic depth and breadth in cancer treatment, potentially laying a strong foundation for future growth.
See More
Zidesamtinib Shows Promising Activity in ROS1-Positive NSCLC Patients
- Significant Clinical Activity: In the ARROS-1 trial, zidesamtinib demonstrated a 41% objective response rate in ROS1-positive NSCLC patients previously treated with repotrectinib or taletrectinib, indicating its potential as a new treatment option for heavily pre-treated patients.
- Enhanced Brain Penetrance: Preclinical studies show that zidesamtinib has superior brain penetrance and antitumor activity compared to existing ROS1 inhibitors, particularly in tumors with the ROS1 G2032R mutation, supporting its potential in earlier lines of therapy.
- FDA Application Progress: The FDA has accepted the New Drug Application for zidesamtinib with a target action date of September 18, 2026, and if approved, it is expected to launch in the U.S. market in 2026, addressing urgent needs for ROS1-positive NSCLC patients.
- Clinical Data Support: Zidesamtinib showed an 11% complete response rate in patients with CNS disease and a 67% objective response rate in those with the ROS1 G2032R mutation, highlighting its potential in treating resistant tumors.
See More
Nuvalent Submits NDA for Neladalkib in Advanced NSCLC
- NDA Submission: Nuvalent, Inc. has submitted an NDA to the FDA for neladalkib, an ALK-selective inhibitor designed for TKI-pretreated advanced ALK-positive NSCLC patients, marking a significant milestone in oncology drug development.
- Clinical Trial Data: The application is supported by data from the ALKOVE-1 Phase 1/2 clinical trial, demonstrating neladalkib's efficacy in TKI-pretreated patients, which enhances its market potential and attractiveness to investors.
- Rapid Development Timeline: Chief Development Officer Darlene Noci noted that the transition from the first clinical trial initiation to NDA submission in less than four years showcases the accelerated pace of oncology drug development, potentially drawing more investor interest in the company's future.
- Positive Market Reaction: Nuvalent's shares rose 0.38% to $104.10 in pre-market trading on Nasdaq, reflecting a positive market response to the NDA submission and confidence in the company's growth prospects.
See More
Nuvalent Submits NDA for ALK-Selective Inhibitor in Advanced NSCLC
- NDA Submission: Nuvalent has submitted an NDA to the FDA for neladalkib, an ALK-selective inhibitor targeting TKI-pretreated advanced ALK-positive NSCLC patients, marking a remarkable four-year timeline from clinical trial initiation to submission, showcasing the company's rapid advancement in oncology drug development.
- Clinical Trial Results: In the global registration-directed ALKOVE-1 trial, neladalkib demonstrated encouraging overall activity in TKI-pretreated patients, including intracranial responses, indicating its potential to address key drivers of disease progression while maintaining a favorable safety profile consistent with its ALK-selective design.
- Breakthrough Therapy Designation: Neladalkib has received FDA breakthrough therapy designation for patients with locally advanced or metastatic ALK-positive NSCLC previously treated with two or more ALK tyrosine kinase inhibitors, highlighting its unique value and market potential in the treatment landscape.
- Future Development Plans: Nuvalent plans to present detailed clinical results at an upcoming medical meeting, further enhancing neladalkib's market acceptance, and is committed to working closely with the FDA to expedite the drug's approval process to meet urgent patient needs.
See More
Guardant Health and Nuvalent Forge Long-Term Partnership to Create Companion Diagnostics and Aid in the Commercialization of Targeted Cancer Treatments via the Guardant Infinity™ Platform
Strategic Collaboration Announcement: Guardant Health has announced a multi-year strategic collaboration with Nuvalent to develop companion diagnostics for targeted cancer therapies.
Focus on Cancer Therapies: The partnership aims to enhance the development of diagnostics that support the commercialization of specific cancer therapies.
Utilization of Technology: The collaboration will leverage the Guardant Infinity™ platform to facilitate advancements in cancer diagnostics.
Potential Impact: This initiative is expected to improve patient outcomes by providing tailored diagnostic solutions for targeted cancer treatments.
See More
Nuvalent Announces Clinical Trial Data Presentation
- Clinical Trial Data Presentation: Nuvalent will present pivotal data for neladalkib in ALK-positive NSCLC patients at the 2026 ASCO Annual Meeting, which is expected to attract investor interest and potentially drive stock price appreciation.
- NDA Progress: The FDA has accepted Nuvalent's NDA for zidesamtinib, with a target action date of September 18, 2026, which, if approved, will provide a new treatment option for patients with ROS1-positive NSCLC, enhancing the company's market competitiveness.
- Breakthrough Therapy Designation: Both neladalkib and zidesamtinib have received breakthrough therapy designation from the FDA, indicating their potential in treating resistant tumors, which may attract further investment and enhance the company's reputation.
- Global Clinical Trial Strategy: The global data presentation from the ARROS-1 and ALKOVE-1 trials demonstrates Nuvalent's ongoing innovation in targeted cancer therapies, potentially laying the groundwork for future market expansion.
See More
Nuvalent Presents Clinical Trial Data for Cancer Treatments
- Clinical Trial Data Presentation: Nuvalent will present pivotal data for neladalkib in ALK-positive non-small cell lung cancer patients at the 2026 ASCO Annual Meeting, which is expected to enhance its market position in oncology.
- NDA Progress: The FDA has accepted the NDA submission for zidesamtinib, with a target action date of September 18, 2026, indicating significant market opportunities for the drug in ROS1-positive non-small cell lung cancer patients.
- Breakthrough Therapy Designation: Both neladalkib and zidesamtinib have received breakthrough therapy designation from the FDA, highlighting their potential in treating resistant tumors and likely attracting increased investor interest.
- Global Clinical Trial Strategy: The global scope of the ARROS-1 and ALKOVE-1 clinical trials demonstrates Nuvalent's strategic depth and breadth in cancer treatment, potentially laying a strong foundation for future growth.
See More
Zidesamtinib Shows Promising Activity in ROS1-Positive NSCLC Patients
- Significant Clinical Activity: In the ARROS-1 trial, zidesamtinib demonstrated a 41% objective response rate in ROS1-positive NSCLC patients previously treated with repotrectinib or taletrectinib, indicating its potential as a new treatment option for heavily pre-treated patients.
- Enhanced Brain Penetrance: Preclinical studies show that zidesamtinib has superior brain penetrance and antitumor activity compared to existing ROS1 inhibitors, particularly in tumors with the ROS1 G2032R mutation, supporting its potential in earlier lines of therapy.
- FDA Application Progress: The FDA has accepted the New Drug Application for zidesamtinib with a target action date of September 18, 2026, and if approved, it is expected to launch in the U.S. market in 2026, addressing urgent needs for ROS1-positive NSCLC patients.
- Clinical Data Support: Zidesamtinib showed an 11% complete response rate in patients with CNS disease and a 67% objective response rate in those with the ROS1 G2032R mutation, highlighting its potential in treating resistant tumors.
See More
Nuvalent Submits NDA for Neladalkib in Advanced NSCLC
- NDA Submission: Nuvalent, Inc. has submitted an NDA to the FDA for neladalkib, an ALK-selective inhibitor designed for TKI-pretreated advanced ALK-positive NSCLC patients, marking a significant milestone in oncology drug development.
- Clinical Trial Data: The application is supported by data from the ALKOVE-1 Phase 1/2 clinical trial, demonstrating neladalkib's efficacy in TKI-pretreated patients, which enhances its market potential and attractiveness to investors.
- Rapid Development Timeline: Chief Development Officer Darlene Noci noted that the transition from the first clinical trial initiation to NDA submission in less than four years showcases the accelerated pace of oncology drug development, potentially drawing more investor interest in the company's future.
- Positive Market Reaction: Nuvalent's shares rose 0.38% to $104.10 in pre-market trading on Nasdaq, reflecting a positive market response to the NDA submission and confidence in the company's growth prospects.
See More
Nuvalent Submits NDA for ALK-Selective Inhibitor in Advanced NSCLC
- NDA Submission: Nuvalent has submitted an NDA to the FDA for neladalkib, an ALK-selective inhibitor targeting TKI-pretreated advanced ALK-positive NSCLC patients, marking a remarkable four-year timeline from clinical trial initiation to submission, showcasing the company's rapid advancement in oncology drug development.
- Clinical Trial Results: In the global registration-directed ALKOVE-1 trial, neladalkib demonstrated encouraging overall activity in TKI-pretreated patients, including intracranial responses, indicating its potential to address key drivers of disease progression while maintaining a favorable safety profile consistent with its ALK-selective design.
- Breakthrough Therapy Designation: Neladalkib has received FDA breakthrough therapy designation for patients with locally advanced or metastatic ALK-positive NSCLC previously treated with two or more ALK tyrosine kinase inhibitors, highlighting its unique value and market potential in the treatment landscape.
- Future Development Plans: Nuvalent plans to present detailed clinical results at an upcoming medical meeting, further enhancing neladalkib's market acceptance, and is committed to working closely with the FDA to expedite the drug's approval process to meet urgent patient needs.
See More
